A Controlled Study of Postoperative Radiotherapy for Patients with Completely Resected Nonsmall Cell Lung Carcinoma. Groupe D'Etude Et De Traitement Des Cancers Bronchiques
Overview
Authors
Affiliations
Background: Postoperative radiotherapy is commonly used to treat patients with completely resected nonsmall cell lung carcinoma, but its effect on overall survival has not been established.
Methods: After undergoing complete surgical resection, 728 patients with non-small cell lung carcinoma (221 Stage I, 180 Stage II, and 327 Stage III) were randomized to receive either postoperative radiotherapy at a total dose of 60 gray or observation only . The main end point was overall survival.
Results: At the reference date, 218 of 355 patients in the control group had died and 262 of 373 in the radiotherapy group had died. Five-year overall survival was 43% for the control group and 30% for the radiotherapy group (P = 0.002, log rank test; relative risk [RR]: 1.33; 95% confidence interval [CI]: 1.11-1.59). This result was not modified by adjustment for potential prognostic factors. The excess mortality rate for the radiotherapy group was due to an excess of intercurrent deaths (P = 0.0001; RR: 3.47; the 5-year intercurrent death rate was 8% for the control group and 31% for the radiotherapy group). Radiotherapy had no significant effect on local recurrence (RR: 0.85; 95% CI: 0.64-1.14) and no effect on metastasis (RR: 1.06; 95% CI: 0.85-1.31). The rate of non-cancer-related death increased with the dose per fraction delivered.
Zhu D, Xiao Y, He S, Xie B, Zhao W, Xu Y Front Surg. 2025; 11:1506854.
PMID: 39968112 PMC: 11832526. DOI: 10.3389/fsurg.2024.1506854.
Yilmaz M, Hurmuz P, Gurlek E, Yildiz D, Cengiz M Strahlenther Onkol. 2024; .
PMID: 39641790 DOI: 10.1007/s00066-024-02339-y.
Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer-A Review.
Suveg K, Plasswilm L, Iseli T, Leskow P, Fischer G, Putora P Cancers (Basel). 2022; 14(7).
PMID: 35406388 PMC: 8997169. DOI: 10.3390/cancers14071617.
A narrative review of postoperative adjuvant radiotherapy for non-small cell lung cancer.
Olmetto E, Perna M, Cerbai C, Aquilano M, Banini M, Mariotti M Mediastinum. 2022; 6:4.
PMID: 35340837 PMC: 8841548. DOI: 10.21037/med-21-31.
Sun X, Men Y, Wang J, Bao Y, Yang X, Zhao M Thorac Cancer. 2021; 12(9):1358-1365.
PMID: 33728811 PMC: 8088942. DOI: 10.1111/1759-7714.13908.